Nektar Therapeutics (Nasdaq: NKTR) today presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking ...

MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant improvements observed in secondary endpoints, including reductions in ...

The Phase 2b ADAPTIVE trial is a randomized, placebo-controlled dose-finding study designed to evaluate the efficacy and safety of various dose regimens of IMG-007 in adults with moderate-to-severe AD ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ...

An oral agent is needed because some patients don’t like injectables, and some doctors don’t prescribe them, experts say.

In patients with atrial fibrillation who had a drug-eluting stent implanted at least 1 year prior, oral anticoagulation alone was noninferior to oral anticoagulation plus clopidogrel, researchers ...

Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while ...

NEW ORLEANS -- The investigational oral PCSK9 inhibitor enlicitide reduced low-density lipoprotein (LDL) cholesterol in ...

FOSTER CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today reported financial results for ...

Rhythm Pharmaceuticals (RYTM) announced that Rhythm and its partners delivered four Rhythm data presentations at ObesityWeek 2025, held last week ...

Fibrotic interstitial lung disease (fibrotic ILD) entails a spectrum of different clinical entities characterised by an ...

NEW ORLEANS -- Innovations in lipid lowering get a major chance to shine, and potentially move the needle in cardiometabolic ...